Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2026)

Top biotech stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Immucell (NASDAQ:ICCC) is the #1 top biotech stock out of 608 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Immucell (NASDAQ:ICCC) is: Value: C, Growth: A, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: C.

Immucell (NASDAQ:ICCC) has a Due Diligence Score of 19, which is -5 points lower than the biotech industry average of 24. Although this number is below the industry average, our proven quant model rates ICCC as a "A".

ICCC passed 6 out of 33 due diligence checks and has weak fundamentals. Immucell has seen its stock return 67.02% over the past year, overperforming other biotech stocks by 50 percentage points.

Exelixis (NASDAQ:EXEL) is the #2 top biotech stock out of 608 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Exelixis (NASDAQ:EXEL) is: Value: A, Growth: B, Momentum: B, Sentiment: C, Safety: C, Financials: A, and AI: B.

Exelixis (NASDAQ:EXEL) has a Due Diligence Score of 45, which is 21 points higher than the biotech industry average of 24.

EXEL passed 15 out of 33 due diligence checks and has strong fundamentals. Exelixis has seen its stock return 25.08% over the past year, overperforming other biotech stocks by 9 percentage points.

Exelixis has an average 1 year price target of $50.20, a downside of -11.15% from Exelixis's current stock price of $56.50.

Exelixis stock has a consensus Hold recommendation according to Wall Street analysts. Of the 10 analysts covering Exelixis, 10% have issued a Strong Buy rating, 20% have issued a Buy, 70% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #3 top biotech stock out of 608 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: C, Momentum: B, Sentiment: B, Safety: C, Financials: B, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 58, which is 34 points higher than the biotech industry average of 24.

AUPH passed 19 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 76.71% over the past year, overperforming other biotech stocks by 60 percentage points.

Out of 6 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 34.45%, which is 28 percentage points higher than the biotech industry average of 6.55%.

Dominari Holdings's dividend payout ratio of -19.1% indicates that its high dividend yield might not be sustainable for the long-term.

Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 6.19%, which is the same as the biotech industry average of 6.55%.

Oramed Pharmaceuticals's dividend payout ratio of 9.4% indicates that its high dividend yield is sustainable for the long-term.

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 2.58%, which is -4 percentage points lower than the biotech industry average of 6.55%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 43.1% indicates that its dividend yield is sustainable for the long-term.

Biotech stocks were down -2.42% in the last day, and down -0.02% over the last week. Virax Biolabs Group was the among the top losers in the biotechnology industry, dropping -35.85% yesterday.

Virax Biolabs Group shares are trading lower. Yesterday, the company announced it signed a $3.3 million agreement for the immediate exercise of 548,000 shares at $6 per share.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 43, which is 31 points higher than the biotech industry average of 12. It passed 3 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 7.31% in the past year. It has underperformed other stocks in the biotech industry by -9 percentage points.

Innoviva (NASDAQ:INVA) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Innoviva has a valuation score of 71, which is 59 points higher than the biotech industry average of 12. It passed 5 out of 7 valuation due diligence checks.

Innoviva's stock has gained 16.68% in the past year. It has performed in line with other stocks in the biotech industry.

Cormedix (NASDAQ:CRMD) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Cormedix has a valuation score of 43, which is 31 points higher than the biotech industry average of 12. It passed 3 out of 7 valuation due diligence checks.

Cormedix's stock has dropped -28.27% in the past year. It has underperformed other stocks in the biotech industry by -45 percentage points.

68.76% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 55.04% over the next year.

2.17% of biotech stocks have a Zen Rating of A (Strong Buy), 4.57% of biotech stocks are rated B (Buy), 45.22% are rated C (Hold), 36.52% are rated D (Sell), and 11.52% are rated F (Strong Sell).